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abstract
This article describes the achievements of the Cutaneous LymphomaTask Force (CLTF)
over the recent decade in their goal to optimize classiﬁcation and response criteria
and establish new treatment options for patients suffering from cutaneous T-cell
lymphomas (CTCL). Collaborative work with the International Society of Cutaneous
Lymphoma (ISCL) and the United States Cutaneous Lymphoma Consortium (USCLC)
has led to publication of pivotal manuscripts proposing revised staging proposals
for Mycosis fungoides (MF)/Se´zary syndrome (SS) and also non MF/SS primary
cutaneous lymphomas as well as the recent publication of a proposal for deﬁning
endpoints in MF/SS.
© 2012 European Organisation for Research and Treatment of Cancer.
1. WHO–EORTC classiﬁcation for cutaneous
lymphomas
Primary cutaneous lymphomas often have a completely
different clinical course and prognosis from histologi-
cally similar systemic lymphomas, which may involve
the skin secondarily, and therefore require different
types of treatment. For that reason, recent classiﬁcation
systems for non-Hodgkin lymphomas such as the
European Organization for Research and Treatment of
Cancer (EORTC) classiﬁcation for primary cutaneous
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lymphomas and the World Health Organization (WHO)
classiﬁcation for tumors of hematopoietic and lymphoid
tissues included primary cutaneous lymphomas as
separate entities. In the EORTC classiﬁcation, distinction
was made between primary cutaneous lymphomas with
an indolent, intermediate, or aggressive clinical behavior.
The clinical validity of this classiﬁcation has been
conﬁrmed by several large studies, including follow-
up data of more than 1300 patients with a primary
cutaneous lymphoma.
Although there was consensus between the EORTC
and WHO classiﬁcations on the classiﬁcation of most
types of CTCLs, remaining differences between the two
classiﬁcation systems, in particular the controversy on
the deﬁnition and terminology of the different types
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of cutaneous B-cell lymphoma (CBCLs), has resulted in
considerable debate and confusion. During consensus
meetings in Lyon, France (September 2003) and Zurich,
Switzerland (January 2004), these differences were re-
solved by representatives of both classiﬁcation systems,
and a consensus classiﬁcation was developed. 1 The
WHO–EORTC classiﬁcation for cutaneous lymphomas
presented in this report may be considered as an
important step forward.
This review will focus on primary cutaneous lym-
phomas and a few other conditions that frequently ﬁrst
present in the skin, such as CD4+/CD56+ hematodermic
neoplasm (formerly also known as blastic natural
killer [NK] cell lymphoma) and adult T-cell leukemia/
lymphoma. Other neoplasms that may also ﬁrst present
in the skin in a minority of cases, such as precursor
B-lymphoblastic leukemia/lymphoma and acute myeloid
leukemia, and secondary cutaneous manifestations
of systemic lymphomas, are not discussed. After a
discussion of the two most controversial groups of
cutaneous lymphomas that were deﬁned differently in
the original EORTC and WHO classiﬁcation schemes, the
main features of the different types of primary cutaneous
lymphoma are presented.
The WHO–EORTC classiﬁcation for cutaneous lym-
phomas presented herein may be considered as an
important step forward. First, the development of this
consensus classiﬁcation will put an end to the ongoing
discussion whether the EORTC or the WHO scheme can
best be used, and is expected to contribute to a more
uniform diagnosis and hence a more uniform treatment
of patients with a cutaneous lymphoma. Second, major
progress has been made in a better deﬁnition of
some controversial groups of cutaneous lymphoma, in
particular the group of primary cutaneous follicle center
lymphoma PCFCL) and the group of CTCL other than
mycosis fungoides (MF), Se´zary syndrome (SS), and the
group of primary cutaneous CD30+ lymphoproliferative
diseases (LPD). The new deﬁnitions of the groups of
PCFCL, PCLBCL, leg type, and PCLBCL, other, will allow
a more reliable distinction between indolent and more
aggressive types of CBCL, and facilitate the decision
whether radiotherapy or systemic chemotherapy should
be selected as ﬁrst choice of treatment.
Large multicenter studies are now required to validate
the current proposals, and in particular to investigate the
diagnostic and prognostic value of bcl-2 and Mum-1/IRF4
protein expression. The classiﬁcation of CTCL other than
MF, SS, and the group of primary cutaneous CD30+ LPD
is still difﬁcult, as it requires accurate clinicopathologic
correlation and a number of complementary tech-
niques to arrive at a deﬁnite diagnosis. Subcutaneous
panniculitis-like T-cell lymphoma (SPTL) (with an alpha/
beta phenotype), extranodal NK/T-cell lymphoma, nasal
type, and CD4+/CD56+ hematodermic neoplasm are now
fairly well deﬁned. However, considerable overlap is
noted between cutaneous (and mucosal) GD-TCL and
aggressive epidermotropic CD8+ CTCL. The similarities
in clinical presentation and pattern of dissemination be-
tween these conditions may reﬂect similarities in hom-
ing proﬁle and biologic function of normal gamma/delta-
positive T -cells and activated CD8+ cytotoxic T cells,
respectively. Apart from the group of SPTLs and the group
of CD4+ small/medium-sized pleomorphic CTCLs, these
rare types of CTCL have a very poor prognosis and are
generally resistant to conventional chemotherapy. More
aggressive regimens, including allogeneic bone marrow
transplantation, for patients with aggressive types of
CTCL including advanced stages of MF and SS are
currently under investigation. This article was one of the
most highly cited articles published in Blood from 2005
through 2010.
In addition, consensus was reached between the
International Society for Cutaneous Lymphomas (ISCL)
and the EORTC CLTF about a new TNM classiﬁcation
system for primary cutaneous lymphomas other than
mycosis fungoides and Se´zary syndrome. 2
2. EORTC consensus recommendations for the
treatment of mycosis fungoides/Se´zary syndrome
Several reviews and guidelines on the management
of mycosis fungoides and Se´zary syndrome (MF/SS)
have been published, however, treatment strategies for
patients with MF/SS vary from institution to institution
and no European consensus has yet been established.
There are few phase III trials to support treatment
decisions for MF/SS, and treatment is often determined
by institutional experience. In order to summarize the
available evidence and review ‘best practices’ from each
national group, the EORTC CLTFmet in September 2004 to
establish European guidelines for the treatment of MF/SS.
These recommendations reﬂect the best data available at
the time the report was prepared. 3
The report reviews the treatment regimens selected
for inclusion in the guidelines and summarizes the
clinical data for treatments appropriate for each stage
of MF/SS. Guideline recommendations are presented
according to the quality of supporting data, as deﬁned
by the Oxford Centre for Evidence-Based Medicine. Skin-
directed therapies (SDT) are the most appropriate option
for early-stage MF/SS and most patients can look forward
to a normal life expectancy. Patients with advanced
disease should be encouraged to participate in clinical
trials and maintenance of quality of life should be
paramount.
In early-stage MF, SDT represents the most appropriate
therapy. Most patients will be able to achieve a
short-term clinical response with recurrent disease
for many years and, in the majority of cases, a
normal life expectancy. Therefore, potentially toxic and
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aggressive therapies should be avoided. Patients with
more advanced stages of MF and patients with SS have
a poor prognosis. In these patients, the absence of
randomized, controlled trials results in a lack of sufﬁcient
evidence to provide a basis for a consensus. None of the
therapies described so far have a documented impact
on disease outcome. Thus, all patients with late-stage
disease should be entered into appropriate clinical trials.
As treatment of MF/SS is always palliative, maintenance
of quality of life should be at the center of therapeutic
strategies.
3. EORTC–International Society of Cutaneous
Lymphoma (ISCL) and United States Cutaneous
Lymphoma Consortium (USCLC) consensus
recommendations for the treatment of primary
cutaneous CD30-positive lymphoproliferative
disorders (lymphomatoid papulosis and primary
cutaneous anaplastic large-cell lymphoma) and for
the management of cutaneous B-cell lymphomas
Various therapeutic regimens have been reported for
primary cutaneous CD30-positive LPD, lymphomatoid
papulosis (LYP) and primary cutaneous anaplastic large-
cell lymphoma (PCALCL). International recommenda-
tions for the management of CD30+ LPD have not yet
been established. W. Kempf, on behalf of EORTC CLTF,
performed a systematic review of therapeutic studies
in CD30+ LPD to assess response and relapse rates
as well as outcome after treatment. Based on these
data and the institutional experience of the EORTC
Cutaneous Lymphoma Task Force, ISCL and USCLC
members, consensus recommendations for CD30+ LPD
were developed. 4
Fifty-two reports on therapy in PCALCL including a
total of 368 patients and 60 reports on therapy in LYP
including a total of 585 patients were analyzed. Most
treatment regimens have been reported in case reports
or smaller retrospective cohorts studies. For solitary or
grouped PCALCL lesions, both surgical excision (SE) and
radiotherapy (RT) achieve complete response rates (CRRs)
of at least 95%. Recurrences occur in approximately
40% of patients and are evenly frequent after both inter-
ventions. Non-interventional strategy with observation
of the natural course may be justiﬁed at least for up
to 8 weeks, since spontaneous regresssion of PCALCL
lesions has been observed in 25% of the patients. CRR to
multiagent chemotherapy as initial therapy was 85% and
62% for CHOP (cyclophosphamide, hydroxydaunorubicin
[doxorubicin], vincristine [Oncovin], Predniso[lo]n). Re-
lapses were observed in 43% of all patients treated
with chemotherapy in general and in 70% of the
patients treated with CHOP. In LYP, UV light therapy
and systemic low-dose MTX result in reduction of the
number of lesions with response rates ranging from
40% to almost 100%. Independent of the therapeutic
approach, sustaining complete remission usually cannot
be achieved and LYP tends to recur quickly after cessation
of therapy. In addition, none of the therapies for LYP
has been unequivocally proven to prevent LYP-associated
second lymphomas.
Treatment of PCALCL should be tailored to the
size and extent of tumoral lesions. SE and RT are
best recommended as ﬁrst-line therapy for solitary
or grouped lesions. Non-interventional strategy with
observation of the natural course may be justiﬁed
at least for up to 8 weeks. For multifocal PCALCL low-
dose methotrexate (MTX) is recommended. Multiagent
chemotherapy is not indicated for multifocal PCALCL
and should be reserved for patients with extracutaneous
spread. For LYP with only a few lesions, abstention
of active therapeutic intervention is a legitimate ﬁrst-
line approach. The best documented treatment regimens
for patients with numerous or disﬁguring LYP lesions
are UV light therapy and systemic low-dose MTX.
Overtreatment with aggressive and potentially harmful
treatment modalities should be avoided. In regard to the
lack of evidence for all reported therapies, prospective
controlled and randomized trials are urgently needed
to evaluate the effect of therapeutic interventions in
CD30+ LPD.
EORTC/ISCL consensus recommendations were also
given for the management of cutaneous B-cell lym-
phomas. It has been highlighted that low-dose radio-
therapy rather than chemotherapy is the standard of care
for low-grade PCBCL. 5
4. Revisions to the staging and classiﬁcation,
clinical endpoints and response criteria in
mycosis fungoides and Se´zary syndrome:
a consensus statement of the International
Society for Cutaneous Lymphomas, the United
States Cutaneous Lymphoma Consortium, and the
EORTC CLTF
Clinical trials in MF/SS have suffered from a lack
of standardization in evaluation, staging, assessment,
endpoints, and response criteria. Recently deﬁned
criteria for the diagnosis of early MF, guidelines for
initial evaluation, and revised staging and classiﬁcation
criteria for MF and SS now offer the potential for uniform
staging of patients enrolled in clinical trials for MF/SS. 6,7
These articles present consensus recommendations for
the general conduct of clinical trials of patients with
MF/SS as well as methods for standardized assessment
of potential disease manifestations in skin, lymph nodes,
blood, and visceral organs, and deﬁnition of endpoints
and response criteria. These guidelines should facilitate
collaboration among investigators and collation of data
from sponsor-generated or investigator-initiated clinical
trials involving patients with MF or SS.
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Trial 1
Lenalidomide
Maintenance
• Stage IIB-IVB MF/SS
• Not appropriate for
skin-directed therapy
• No prior systemic
chemotherapy
Patients who respond
to gemcitabine
debulking are
randomized
Trial 2
SAHA vs
SAHA + bortezomib
• Stage IIB-IVB MF/SS
• Not appropriate for
skin-directed therapy
• Relapsed / refractory
• No prior tx with either
agent
EMBT
Allo-SCT after
Reduced Intensity
Conditioning Protocol
Embedded study of
photophoresis
• Stage IIB-IVB MF/SS
• Having progressed on
prior systemic
chemo
Fig. 1 – Eligibility criteria for platform.
5. The EORTC Cutaneous T-Cell Lymphoma (CTCL)
Platform
The EORTC CLTF has recently successfully completed
two clinical trials in CTCL (EORTC 21011/21012) which
have been presented at the ASH Annual Meeting 2010 8
and are now submitted for publication (21012) or are
due for publication soon (21011). In an effort to target
this rare disease more effectively, the CTCL platform has
been designed by the EORTC CLTF to address critical
unadressed questions to move forward the standards
of care of CTCL in advanced-stage disease. It was built
following a sequential approach. Following a European
consensus deﬁning the key clinical questions to improve
disease control in CTCL, ideas regarding the biology of
the disease and all possible emerging targets which
may lead to a better understanding of the disease
were explored. The candidate targets were selected
and prioritized by their scientiﬁc and clinical relevance.
The maturity and relevance of agents in development
to tackle these pathways and targets were analyzed.
Methodologically and statistically robust clinical trials
were designed to allow the enrollment of patients
through the evolution of their disease. Endpoints and
translational research programs that could address and
help identify mechanisms of action and clinical efﬁcacy
were also evaluated as to feasibility and scientiﬁc
relevance. This comprehensive process led to the design
of early phase randomized trials on solid scientiﬁc
grounds with the use of innovative drugs.
Study protocol 21081 is a multicenter, randomized,
open-label, phase III study and is suitable for patients
who have not previously had other intravenous chemo-
therapy, and are therefore relatively treatment-naive.
The accrual goal is 105 patients. The objective of this
trial is to test the hypothesis that lenalinomide is
able to increase progression-free survival in patients
achieving a complete (CR) or partial (PR) response after
standardized debulking treatment. A sister protocol,
21082, addresses patients who have had previous
chemotherapy. Patients in this study will be randomized
to receive the histone deacetylase inhibitor vorinostat
alone or in combination with the proteasome inhibitor
bortezomib. The primary objective of this trial will be
to determine if the combination of bortezomib plus
vorinostat is more effective than vorinostat alone in
prolonging progression-free survival. The accrual goal is
189 patients. In both studies, validation of new proposed
response criteria 4 is foreseen.
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